CC312

( DrugBank: - / KEGG DRUG: - )


5 diseases
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis1
49Systemic lupus erythematosus1
51Scleroderma1
IDDisease name (Link within this page)Number of trials
61Autoimmune hemolytic anemia1
63Idiopathic thrombocytopenic purpura1

46. Malignant rheumatoid arthritis


Clinical trials : 4,543Drugs : 2,251 - (DrugBank : 390) / Drug target genes : 198 - Drug target pathways : 232 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

49. Systemic lupus erythematosus


Clinical trials : 1,227Drugs : 752 - (DrugBank : 175) / Drug target genes : 130 - Drug target pathways : 207 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

51. Scleroderma


Clinical trials : 639Drugs : 551 - (DrugBank : 157) / Drug target genes : 135 - Drug target pathways : 222 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

61. Autoimmune hemolytic anemia


Clinical trials : 183Drugs : 119 - (DrugBank : 42) / Drug target genes : 31 - Drug target pathways : 156 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

63. Idiopathic thrombocytopenic purpura


Clinical trials : 575Drugs : 261 - (DrugBank : 64) / Drug target genes : 61 - Drug target pathways : 142 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries